Alli News Abstract 30
http://www.fleshandstone.net/healthandsciencenews/1744.html
Sibutramine, the controversial appetite suppressing drug used by many obese patients in the USA, is said to pose excessive risks of cardiovascular and other complications.
The sibutramine ban may be received as very bad news for obese French and European citizens who, due to stringent health safeguards, already have a very limited range of legal drugs available to help them lose weight.
France’s Agency for the Sanitary Safety of Health Products (AFSSAPS) decided this week to take sibutramine –- sold in France since 2001 under the brand name Sibutral –- off the list of approved prescriptions in advance of an upcoming Europe-wide decision on its safety risks by the EU’s health commission. It is widely expected that the drug will be banned in European countries. Great Britain has already suspended its use.